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Summary Data from a completed randomized trial in breast cancer are used to demonstrate and quantify the variation in estimated survival
curves and log-rank statistics at different times throughout a trial. False 'plateaux' are common, as are wide fluctuations in x2 values obtained
from the log-rank test when there are few events. We show how analyses conducted at different times can demonstrate different effects. Long
follow-up is often necessary to allow correct interpretation of results. We discuss the assumption of proportional hazards and the
consequences of making that assumption inappropriately. We show how checking whether hazards are proportional can help in avoiding
erroneous conclusions.
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Randomized clinical trials of cancer therapies are often conducted
using survival or progression-free survival as end points. In the
design of such studies sample sizes and trial durations are usually
fixed, using power calculations of the type tabulated by Machin
and Campbell (1987). Sequential designs, involving a series of
interim analyses with the potential for reducing sample size and
trial duration, are being used increasingly in cancer survival
studies (Whitehead, 1993; Fayers et al, 1994), although concern
has been expressed over their inappropriate use (Souhami, 1994).
Trial reports usually present Kaplan-Meier curves (Kaplan and
Meier, 1958) and use the log-rank test (Peto et al, 1977) or Cox's
regression analysis (Cox, 1972) to assess treatment differences.
The limitations of these methods, and their dependence on
modelling assumptions, are well known to statisticians. These
issues are explained in technical terms in introductory texts on
survival analysis (see for example Collett, 1994; Parmar and
Machin, 1995). However, such limitations are not fully appreci-
ated by many readers, or indeed writers, of clinical trial reports.
The purpose of this paper is to illustrate the potential pitfalls of
survival analysis in a less technical manner, through the detailed
reanalysis of a particular dataset. A computer program is intro-
duced that can be useful in demonstrating these issues to students
and to others working in the field ofclinical cancer research.
The issues thatconcern us relate to the lackofappreciation ofthe
uncertainty inherent in sample size calculations and Kaplan-Meier
curves, of their instability when the number of events is small and
ofthe influence ofthe timing ofa statistical analysis on the conclu-
sions that may be drawn from a study. The accuracy ofsample size
calculations and the role of timing of analysis are related to an
assumption that underlies most survival analysis methodologies,
i.e. that ofproportional hazards. This assumption is described in
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detail in the next section. Subsequently data from a completed trial
in breast cancer are introduced and subjected to a series ofanalyses
to demonstrate the effects of timing. The option of conducting a
mid-study review to reassess the validity of proportional hazards
and the number of patients required is illustrated. Finally, simple
methods for checking the proportional hazards assumption are
presented, and the issues raised in the paper are discussed.
THE PROPORTIONAL HAZARDS ASSUMPTION
The term proportional hazards has a precise mathematical defini-
tion that is difficult to explain in non-technical terms. Its essential
meaning is easier to understand. Suppose that treatment A is more
effective than treatment B. Suppose also that the event rate on
treatment A is lower than that on B for the initial phase offollow-
up (soon after the start oftreatment) and for an intermediate phase
also; in addition, long-term prognosis is better. Treatment A wins
over every phase of follow-up, and (in some mathematical sense)
it wins to the same extent. This is proportional hazards. A counter
example might be a comparison of a surgical procedure (A) with
chemotherapy (B). Because of operative mortality, A might be
associated with a higher death rate in the short term, this being
compensated by fewer deaths during the intermediate phase and a
better long-term prognosis. Such a situation clearly violates the
assumption of proportional hazards as A does not win over every
phase offollow-up.
Ifit is assumed that the hazards of an event on treatments A and
B are proportional, then evidence ofreduced mortality on A during
the immediate post-randomizaton phase will imply that A has
medium and long-term benefits as well. Thus, under this assump-
tion of proportional hazards, data from a large number of subjects
who are followed for a short time will be regarded as being as infor-
mative as data from a few subjects treated for a long time. If
survival times tend to be short, then in the absence of any contra-
dictory medical features of the treatments, a proportional hazards
assumption mightbe appropriate. Forcomparisons ofthe long-term
effects oftherapy, the assumption should be used with caution.
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Figure 1 The overall survival of (A) patients randomizei
therapy or no hormone therapy (log-rank x2 = 3.56, P = 0
patients randomized to chemotherapy or no chemotheral
%2 = 1.74, P = 0.19). HT, hormone therapy
When the assumption of proportional hazard,
approximately, methods based on this assumpti
cient analysis and a simple quantification of ber
single measure, i.e. the hazard ratio. Estimate
intervals can be calculated for this quantity and
its value can be tested. Roughly speaking, the
ratio of the risk of an event during a short pei
using treatment A to that using treatment B.
advantageous then this ratio will be less than
hazards remain proportional will this ratio be
periods of follow-up. If hazards are non-prop(
hazard ratio becomes a form of average of the
apply during different periods of follow-up
progresses, information will come from a changi
ofpatients' follow-up. In the absence ofproporti
will cause fluctuation in the average hazard rati
native presentation of the treatment comparisi
hazard ratios for different periods ofpatient follc
The illustration below concerns a series ofalter
the-same clinical trial made on different dates. In o
this example, it is essential to realize that two dii
are involved. One, patient time is the time since
an individual patient. When events are described
or late during follow-up, it is the patient time scale that is being
considered. The other scale is study time, which is the time since
the start of the clinical trial at which an analysis is performed.
Analyses are classified as early or late on this scale. The two time
scales are connected in that an early analysis will concern exclu-
sively evidence from early events during follow-up, whereas a late
analysis will include events covering a wide range of times since
randomization.
THE COMPLETED TRIAL
lb An EORTC trial of treatment for locally advanced breast cancer is
used for illustration. This trial was chosen because one part of it
6 7 8 was almost stopped prematurely after an apparent early survival
difference on an interim analysis. A total of 410 patients were
recruited to this trial between December 1979 and November
1985. Patients were randomized to receive radiotherapy alone,
radiotherapy followed by chemotherapy, radiotherapy followed by
hormone therapy or radiotherapy followed by both chemotherapy
and hormone therapy. Further details and the results of this
completed study were published in 1989 (Rubens et al, 1989), and
the stopping of the study is discussed in a later paper (Sylvester et
al, 1994). The trial design required analysis of the results after the
admission of a minimum of 330 patients. The published analysis
was conducted 8 years from the start of the study. Data from 363
evaluable patients, extracted in March 1988 from the database,
were used for the published analysis. Interim analyses had been
undertaken as deemed necessary by the trial committee.
Figure 1 shows the survival curve estimates derived from the
6 7 8 two major comparisons (chemotherapy vs no chemotherapy,
hormone therapy vs no hormone therapy). These same compar-
d to hormone isons will be used for our illustrations. The survival curves have
.06) and (B) been calculated using 363 evaluable patients whose data were
py (log-rank available to the trialists at the time ofthe analysis (March 1988)
and which was later published. In the published report, these
results were interpreted as showing no conclusive survival benefit
for either hormone therapy or chemotherapy in locally advanced
breast cancer.
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A series of analyses over study time
The data for our re-analyses were obtained from existing trial data-
bases. The same 363 evaluable patients as featured in the
published March 1988 analysis have been included, but a longer
follow-up period to nearly 10 years (August 1989) has been used.
Our objective was to use the final data set to include as much data
as possible. We refer to this 10-year analysis as thefinal analysis.
For each patient entered into the trial, the dates of entry, death
and last follow-up were obtained. A computer program was written
to draw Kaplan-Meier estimates ofsurvival curves repeatedly from
the data available at specified times after the start of a trial. For
each partly complete data set, a log-rank test was also performed.
The computer program displays the Kaplan-Meier curves for the
two treatment groups under comparison. The program enables the
previous set of survival curves to be erased from the computer
screen by redrawing them in black. However, by over-writing the
curves in different colours, all previous curves can be depicted.
Thus, as the trial progresses, a shaded region for each arm is
produced, showing the fluctuations as the data accumulate in each
ofthe survival curves. (Details ofthis program, which is ofconsid-
erable value in training, can be obtained from WMG.)
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Figure 2 The survival curves for patients randomized to hormone therapy (HT) or no hormone therapy (no HT), together with the overwriting of all
previous survival curves made at 30 day intervals. Light shading, previous curves for HT; dark shading, previous curves for no HT. The final curves are drawn
at day 3630
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Figure 3 The X2 and P-values measured at each 30 log-rank day analysis
of HT versus no HT up to day 3660
Figure 2 shows these superimposed survival curves for the
hormone therapy comparison as they would have appeared at
analyses conducted every 30 days after the start of the study. The
interval of30 days was selected to enable a detailed but clear illus-
tration. The solid line represents the survival curve at the final
analysis; it is different from that shown in Figure IA because of
the longerfollow-up and it shows a significant advantage in favour
of hormone therapy. The superimposed curves show that, with
early analysis, there are numerous false 'plateaux' and separations
of the curve. Those curves that date from 4 years after the start
72 10o
N
Study time (years)
Figure 4 The hazard ratio for the HT vs no HT comparison. The horizontal
line (hazard ratio 1) is the line of equivalence. The solid curve is the
observed hazard ratio and the dashed lines represent the 95% Cl. Ratio < 1
represents an advantage to hormone therapy
of the study begin to show a distinct separation between the
treatments, which becomes more obvious with later curves as the
study time progresses. The time depicted as 4 years cannot be
identified from Figure 2 as this is over patient time, but it is clearly
evident from the computer display of the survival curves as the
serial analyses are made beyond 4 years after the start ofthe study.
The marked dependence of the estimate of survival pattern on the
study time at the point of analysis is shown by the shaded area of
superimposed curves. The time an analysis affects a graph plotted,
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Figure 5 Survival curves for patients randomized to chemotherapy (CT) or no chemotherapy (no CT), with the previous curves overwritten (as in Figure 2) in
light (CT) and dark (no CT) shading
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Figure 6 X2 values plotted at each 30-day point for the CT and no CT
comparison
using patient time as curves plotted at analyses soon after the start
ofthe study, will be estimated only from patients in an early phase
offollow-up. The false 'plateaux' arise because very few patients
have reached that portion ofpatient time. As the study progresses,
the curves are estimated frompatients with initial and intermediate
follow-up and finally from patients in a mix ofinitial, intermediate
and long-term follow-up. As aresult, more ofthe curve is based on
large samples and the occurrence offalse 'plateaux' moves to later
patienttimes. The variablity ofthe data is well demonstrated and is
especially pronounced at the 'tails' of the curves where the
number ofobservations is smaller.
In Figure 3, we show the X2 values from each of the successive
analyses of hormone therapy computed from the log-rank test.
Certain reference P-values are indicated by horizontal lines. A
benefit of hormone therapy is suggested temporarily, 2 years into
the study. Significance then disappears, followed by a slow rise in
the value ofX2 from 4 years to the final analysis at which there is a
highly significant P-value. This progress is not steady, with a brief
temporary fall in x2 just before 8 years. By chance, it was just at
this point that the trial was analysed and the results presented.
Figure 4 shows the estimated hazard ratio and its associated confi-
dence limits to illustrate theprecision ofthese estimates foreach of
the successive analyses. Until 4 years into the study, these values
fluctuate greatly, after which they assume more constant values.
These graphical representations show the inherent instability of
the estimated survival curves, especially during the early phases of a
trial. Similar effects are seen for the chemotherapy comparison. In
Figure 5, the series ofcurves forthe serial analyses every 30days are
shown for patients receiving or not receiving chemotherapy. The
false plateaux and variability of the curves are even more apparent
than in the hormonetherapy comparison. TheX2values forthecorre-
sponding log-rank tests are shown in Figure 6. It can be seen that
there is agenerally rising trend towards statistical significance from 2
to 5 years afterthe trial started. In fact aninformal interim analysis at
this stage almost led to discontinuation ofthe study (Sylvester et al,
1994), although itmustberemarked thatnone ofthecommonly used
sequential designs would have led to stopping. This trend is reversed
at 6 years and, atthe final 10-year (August 1989) analysis, there is no
conventionally significant difference between the two treatments.
Figure 7 shows the estimates and confidence limits for hazard ratio;
values only achieve stability after 6 years ofthe study.
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Figure 7 Hazard ratios for the CT vs no CT comparison wit
(dashed lines). A hazard ratio < 1 represents a benefit to che
If an analysis using evaluable patients had been
some of the time points between 3 and 5 years aftei
ofthe trial, chemotherapy would have been found tc
icant effect, with a hazard ratio estimated to
Hormone therapy would have been non-significant
ratio estimated to be about 0.8. This is in con
published analysis in which chemotherapy was stal
significant benefit. It also differs from the final
which again found no significant chemotherapy e
showed hormone therapy to be significantly benefic
Figures 2 and 5 display the results of about
analyses. The corresponding X2 values change as
accumulation of evidence, and over time the estim
ratio become more stable with narrower confide
showing the greater precision of these estimates.
differences in the X2 values because of the natural
tion inherent in any set of accumulating data. Whi
mates of the hazard ratio shown in Figure 4 ((
appropriate? The answer is probably none of them,
that hazards are proportional. Part of the heterogene
mated hazard ratios is likely to be as a result of ti
being proportional. For example, some treatments
sient benefit and others (such as hormone therapy)
durable benefit, and hence the estimated hazard ratic
across study time. If the hazards are proportional,
hazard ratio will-remain relatively constant whate'
period ofpatients' follow-up.
CHECKING THE ASSUMPTION OF
PROPORTIONAL HAZARDS
How can lack ofproportionality of hazards be asses
mated hazards for each of six intervals of patient ti
for hormone therapy (Figure 8A) and chemotherap
Also presented are the hazard ratios (hormon
hormone therapy and chemotherapy-no chemothern
intervals were chosen in advance so as to include
equal numbers of deaths. The final Kaplan-Meier p
shows a steady advantage of hormone therapy witi
endorsed by the hazard plot (Figure 8A) in which
in hazard as a result of hormone therapy is pres
similar magnitude in each of the six time intervals. The final
Kaplan-Meier plot in Figure 5 shows a survival advantage for the
chemotherapy group for the first 2 years of treatment, which
narrows during the 3rd and 4th year and then widens again. The
corresponding hazard plot (Figure 8B) shows that, during that
middle portion, the death rate on chemotherapy actually exceeds
r-"---------- ^ _ that without chemotherapy. Far from being proportional over time,
the hazard ratio for each time period fluctuates from favouring the
chemotherapy group to favouring no chemotherapy and back again
-. - - over the course of follow-up.
There is a relationship between the plots in Figures 6 and 8B.
Note that Figure 6 is plotted in study time, while Figure 8B is in
patient time. Early in the study, only short-term follow-up data are
-+----------, available for all patients. The short-term advantage of chemo-
8 10 therapy predominates. The X2 value is therefore high, and the hazard
ratio estimate is small. Later, the data include patients in the middle
th 95% Cl part of their therapy, at which time patients on chemotherapy are
3motherapy dying more rapidly than those on the control arm. The x2 value falls,
and the hazard ratio estimate rises. Finally, data from late therapy
alsojoin the analysis, and the X2 values stabilize.
i performed at Plots such as those shown in Figure 8 are simple but useful
r the inception checks of the assumption of proportional hazards. A more formal
have a signif- statistical test ofthe assumption based on similar ideas is described
be about 0.6. by Bolland and Whitehead (in preparation), together with alterna-
with a hazard tive forms of analysis if the assumption fails. These methods do
trast with the suffer the limitation of being dependent on the choice of time
ted to have no periods into which the follow-up is split. These intervals should
trial analysis, have some medical relevance and be specified before the study.
-ffect but also More sophisticated statistical alternatives are mentioned in that
ial. paper. If model checking confirms that the assumption of propor-
100 different tional hazards is at least approximately valid, then conventional
a result of the survival analyses can be confidently presented.
ates of hazard Model checking before the application of an analysis that
-nce intervals, depends on proportional hazards is important. However, if the
There are also sample size and trial duration have been fixed by power consider-
random varia- ations arising from the proportional hazards model, checking after
ich of the esti- recruitment has closed may come too late. It may reveal that
or 7) is most hazards are not proportional and that the size and duration of the
as all assume study are inadequate. For this reason, it might be wise to perform a
-ity of the esti- check of proportional hazards as part of a mid-study review while
he hazards not the trial is still open to recruitment. Such an approach enables the
produce tran- prevention of such mistakes by allowing the study to be extended
later but more if necessary. This bears resemblance to the ideas of Gould (1992)
a will fluctuate in the simpler context of trials with success or failure as the
,the estimated primary response.
ver the mix of For illustration, a mid-study review was conducted on the
EORTC data as available on 1 June 1984, approximately 4.5 years
after its inception. By this time, there were data for 296 evaluable
patients, ofwhom 83 had died. Analysis ofthe data available at the
mid-study review using the conventional log-rank test revealed
that chemotherapy had a significant advantage (%2 = 4.86, P =
ssed? The esti- 0.028). The corresponding estimate of the hazard ratio for
ime are shown chemotherapy relative to placebo was 0.62 with 95% confidence
y (Figure 8B). interval 0.40-0.95. Forhormone therapy, the log-rank test revealed
ie therapy-no that hormone therapy had no significant effect (X2 = 1.21, P =
apy). The time 0.271), resulting in a hazard ratio of 0.78 with 95% confidence
approximately interval 0.51-121.
)lot in Figure 2 At the mid-study review, we also performed graphical model
h time. This is checking ofthe assumption ofproportional hazards using the esti-
the reduction mated hazards for four periods of patient time. For hormone
sent and is of therapy, the hazard ratio favoured treatment in each time period.
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Figure 8 The hazard ratio for (A) HT vs no HT at six intervals of patient time and (B) CT vs no CT at six intervals of patient time
However, for chemotherapy, the hazard ratio was favourable for
treatment for the first 14-month time interval of the trial and was
less favourable forthe 14 to 22-month interval. In the third interval
from 22 to 28 months, the death rate on chemotherapy exceeds that
on no chemotherapy, but it returns to favouring chemotherapy in
the fourth interval, 29-40 months. The hazard ratio is therefore far
from being proportional. Careful consideration might be given at
this stage to the adequacy ofthe planned sample size and the dura-
tion offollow-up for the trial. Plans for interim analyses and stop-
ping rules could also be revised.
DISCUSSION
It is sometimes difficult for both clinicians and statisticians
involved in clinical trials to visualize the instability of survival
data and to appreciate how the results may vary with time. The
graphical illustrations we have provided may help in promoting
scepticism oftrial results that are presented afterearly analysis and
in which only a few hundred patients have been randomized. They
also make it incumbent on investigators to consider trial design
carefully, and to explain how this design was derived, and how
model checking has been performed in their trial report. The data,
which were taken from a completed trial, show the wide fluctua-
tions in estimates of survival, false plateaux and large confidence
intervals typical of early analysis when the number of events is
still small. The analysis of this particular trial shows how, with
time and increasing numbers of events, the true picture becomes
clearer, although the precision of the estimate of the survival
difference remains relatively poor because ofthe size ofthe trial.
The methods of survival analysis that are nowadays conven-
tional were introduced during the 1970s. Peto and Peto (1972)
described the log-rank test and Cox (1972) the proportional
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hazards regression model. Papers such as those by Peto et al
(1977) popularized the methodology among medical researchers.
The log-rank test is a significance test of the equality of the two
survival distributions. The significance level is calculated under
the null hypothesis ofequality and does not depend on the form of
the common survival distribution. Thus, it is non-parametric as it
does not depend on any distributional assumptions. The log-rank
test makes efficient use ofthe data only ifthe proportional hazards
assumption is valid. This means that the test will have high power
to detect a constant hazard ratio not equal to one. If a treatment
was associated with a higher death rate in the short-term but had a
good longer-term prognosis compared with control, then the
hazards would be non-proportional; in fact they would cross. This
would lead to a log-rank test with a X2 value close to zero, incor-
rectly indicating no treatment effect.
Unless the assumption of proportional hazards is valid, the
timing of an analysis can have a substantial effect on its conclu-
sion, as we have demonstrated. The quotation of a single hazard
ratio estimate from a survival study obviously presupposes at least
approximate proportionality of hazards. Otherwise the trial find-
ings have to be summarized through a series of hazard ratio esti-
mates pertaining to different patient-time intervals or using some
other non-constant presentation. Cox's regression analysis allows
more complicated modelling, but it still relies on an assumption of
proportional hazards and, when applied to two treatments in the
absence of other covariates, it is essentially the same as the log-
rank test.
For the trialist, the assumption of proportional hazards presents
difficulties. Conventional calculations of sample size and study
duration for survival trials are based on the proportional hazards
assumption (Freedman, 1982; Machin and Campbell, 1987).
Sequential designs tend also to require this assumption
(Whitehead, 1993). The assumption ofproportional hazards needs
careful consideration at the design stage. Model checking of
previous trials may cast doubts on its validity. Consideration ofthe
mode of action of an experimental treatment might indicate, for
example, that short-term mortality will be increased as the price
for long-term benefit or, conversely, that benefits will affect short-
term survival and quality of life but not the chances of survival
beyond 1 year. In either case the assumption of proportional
hazards is likely to be incorrect. An alternative summary measure
of treatment advantage must be sought - not the (assumed
constant) hazard ratio but perhaps the ratio ofodds on survival past
1 year or the 'averaged' hazard ratio over 1 year. Calculations of
sample size and study duration, and sequential methods can be
based on these alternative measures. Either of the choices above
will lead to studies requiring a substantial number of patients with
at least 1 year offollow-up, or to sequential designs in which stop-
ping is impossible before data on patients who have completed the
whole of the 1st year of treatment begin to accumulate. In some
diseases, it may be necessary to substitute 5 years for 1 year.
Unless there are disastrous short-term results, these will have to be
long studies, even if a sequential design is used.
In some cases, absolutely nothing will be known about the
likely form of hazard ratios. The proportional hazards assumption
perhaps leads to the default design. Post-trial model checking may
either confirm this assumption or indicate that a further trial with a
more suitable design is necessary. It is wise to plan for a long
follow-up period ifpossible, especially iftherapy is short term and
irreversible (e.g. surgery) rather than long term with potential
continuous harm (e.g. life-long drug therapy). This will allow any
late evidence of treatment effect and of non-proportionality of
hazards to emerge. We have shown how a mid-study review might
be used so that the trial design might be revised to take account of
emerging evidence about relative hazards. Such a review could be
used as a prospective tool in a clinical trial - but caution is needed.
First, at this relatively early stage, there will be little power to
detect even serious departures from proportional hazards as being
significant, and conversely misleadingly clear but non-significant
patterns might arise. Second, as the review is not blind to treatment
it could reveal such large survival differences that the trial has to
be stopped. Rather than ignoring the latter possibility, it may be
best to incorporate the review as the first (and possibly only) look
within a formal sequential design. This will protect against infla-
tion of risks of error and, in the case of pharmaceutical trials,
satisfy regulatory requirements. We are not, on the other hand,
going so far as to urge formal allowance for repetition ofthe model
checking nor for its own effects on the final analysis.
If model checking confirms that the assumption of proportional
hazards is at least approximately valid, then conventional analyses
can be confidently presented; if serious departures from propor-
tional hazards are present, then the situation is less clear. Few alter-
native methods have been extensively discussed in the statistical
literature (Kalbfleisch and Prentice, 1981; Pepe and Fleming 1989).
The variability of data, especially early in a trial, and the fact
that hazards may not be proportional means that clinicians must be
cautious about accepting trial results at face value, especially when
large early differences have led to early stopping of a study. Data
monitoring committees in particular should be exceedingly
cautious about stopping randomized trials when early effects
occur, even if clearly significant by conventional tests. We can be
more confident of a result when the trial size is very large and the
follow-up time is long. Alas, this competes with other priorities in
clinical research, such as the need to complete trials quickly and
the need to ask the next, and most urgent, question.
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